Clinical Trials · NCT05086445
A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 62
- Start date
- Nov 2021
- Locations
- 5 sites, Japan
- Primary endpoint
- Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration